Literature DB >> 18645919

Tissue factor and protease-activated receptor signaling in cancer.

Florence Schaffner1, Wolfram Ruf.   

Abstract

The activation of the coagulation cascade in the tumor microenvironment is a key feature of advanced malignancies. On tumor cells, tissue factor (TF) plays a central role to initiate cross-talk through the release of procoagulant microparticles or through direct, protease-activated receptor (PAR)-mediated cell signaling that leads to the production of soluble cytokines and angiogenic growth factors. In addition, the hemostatic system in the host compartment sustains crucial circuits that promote metastasis and support tumor growth and angiogenesis. Experimental tumor and genetic models have defined specific pathways that are supported by tumor cell and host TF and have identified potential therapeutic modalities to specifically interrupt TF signaling in tumor biology without impairment of hemostatic functions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18645919     DOI: 10.1055/s-2008-1079254

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  15 in total

1.  The pro-migratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas.

Authors:  Stephan Dützmann; Florian Gessler; Patrick N Harter; Rüdiger Gerlach; Michel Mittelbronn; Volker Seifert; Donat Kögel
Journal:  Cell Adh Migr       Date:  2010 Oct-Dec       Impact factor: 3.405

2.  Engineering of substrate selectivity for tissue factor.factor VIIa complex signaling through protease-activated receptor 2.

Authors:  Katrine S Larsen; Henrik Ostergaard; Ole H Olsen; Jais R Bjelke; Wolfram Ruf; Lars C Petersen
Journal:  J Biol Chem       Date:  2010-04-13       Impact factor: 5.157

Review 3.  The role of type II transmembrane serine protease-mediated signaling in cancer.

Authors:  Lauren M Tanabe; Karin List
Journal:  FEBS J       Date:  2016-12-24       Impact factor: 5.542

4.  Proteolytic cleavage of Podocin by Matriptase exacerbates podocyte injury.

Authors:  Shota Ozawa; Masaya Matsubayashi; Hitoki Nanaura; Motoko Yanagita; Kiyoshi Mori; Katsuhiko Asanuma; Nobuyuki Kajiwara; Kazuyuki Hayashi; Hiroshi Ohashi; Masato Kasahara; Hideki Yokoi; Hiroaki Kataoka; Eiichiro Mori; Takahiko Nakagawa
Journal:  J Biol Chem       Date:  2020-09-09       Impact factor: 5.157

5.  Coagulation factor VIIa-mediated protease-activated receptor 2 activation leads to β-catenin accumulation via the AKT/GSK3β pathway and contributes to breast cancer progression.

Authors:  Abhishek Roy; Shabbir A Ansari; Kaushik Das; Ramesh Prasad; Anindita Bhattacharya; Suman Mallik; Ashis Mukherjee; Prosenjit Sen
Journal:  J Biol Chem       Date:  2017-05-18       Impact factor: 5.157

6.  Tissue factor pathway inhibitor attenuates the progression of malignant pleural mesothelioma in nude mice.

Authors:  LaTerrica Williams; Torry A Tucker; Kathy Koenig; Timothy Allen; L Vijaya Mohan Rao; Usha Pendurthi; Steven Idell
Journal:  Am J Respir Cell Mol Biol       Date:  2011-08-18       Impact factor: 6.914

7.  Tumors, ticks and tissue factor.

Authors:  T McEachron; N Mackman
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

8.  Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer.

Authors:  Florian Moik; Florian Posch; Ella Grilz; Werner Scheithauer; Ingrid Pabinger; Gerald Prager; Cihan Ay
Journal:  Thromb Res       Date:  2020-01-07       Impact factor: 3.944

Review 9.  Activation of blood coagulation in cancer: implications for tumour progression.

Authors:  Luize G Lima; Robson Q Monteiro
Journal:  Biosci Rep       Date:  2013-09-04       Impact factor: 3.840

10.  Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis.

Authors:  K U Sales; S Friis; J E Konkel; S Godiksen; M Hatakeyama; K K Hansen; S R Rogatto; R Szabo; L K Vogel; W Chen; J S Gutkind; T H Bugge
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.